AstraZeneca COVID-19 vaccine candidate testing will continue. (Figurative)
Highlight
- The Brazilian health authority said a volunteer from a vaccine trial died
- The trial would have stopped if the volunteer had received the vaccine: Sources
- So far, 8,000 of the 10,000 planned volunteers have been recruited.
Sao Paulo / Frankfurt:
Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford had died, but added that the trial would continue.
Oxford confirmed the plan to continue testing, saying in a statement that after careful evaluation “there have been no concerns about the safety of the clinical trial.”
AstraZeneca declined to comment immediately.
A source familiar with the matter told Reuters that the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine, suggesting that the person was part of the control group that received a meningitis injection.
The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, said an independent review committee also recommended that the trial continue. The university previously confirmed that the volunteer was Brazilian, but did not provide further personal details.
“Everything is progressing as expected, with no record of serious vaccine-related complications involving any of the participating volunteers,” the Brazilian university said in a statement.
So far, 8,000 of the 10,000 volunteers expected in the trial have been recruited and given the first dose in six cities in Brazil, and many have already received the second injection, a university spokesman said.
CNN Brazil reported that the volunteer was a 28-year-old man who lived in Rio de Janeiro and died of complications from COVID-19.
Anvisa did not provide further details, citing the medical confidentiality of those involved in the trials.
AstraZeneca shares fell 1.8%.
Brazil’s federal government has plans to buy the vaccine from the United Kingdom and produce it at the FioCruz biomedical research center in Rio de Janeiro, while the Butantan Institute research center at the São Paulo state research center is testing a competing vaccine. from China Sinovac Biotech Ltd.
Brazilian President Jair Bolsonaro said Wednesday that the federal government will not buy the Sinovac vaccine.
Brazil has the second deadliest outbreak of the coronavirus, after the United States, with more than 154,000 deaths. It has the third highest number of cases, with more than 5.2 million infected, after the United States and India.
.
